首页> 外文期刊>European journal of pain : >Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings.
【24h】

Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings.

机译:在一般实践中,患有周围神经痛的痛苦患者的临床特征和疼痛管理。

获取原文
获取原文并翻译 | 示例
       

摘要

Alleviating chronic pain is a global healthcare priority. Understanding the medical profile and current treatment patterns in patients with painful neuropathic disorders (PNDs) is crucial to the development of effective pain management strategies. Thus, our objective was to describe the demographic and clinical characteristics of persons with PNDs and their use of pain medications. Using the general practice research database, we categorized PNDs in two ways: Pure PNDs (which include diabetic neuropathy, postherpetic neuralgia, etc.; N=16,690) and Mixed PNDs (which include backeck pain with neuropathic involvement; N=14,309). On average, PND patients were 55 years old (Pure, 55.4 [SD=16.9] years; Mixed, 54.3 [SD=16.4] years). Over a third had other chronic pain-related (Pure, 37.5%; Mixed, 37.1%) and nearly a quarter had non-pain related (Pure, 28.1%; Mixed, 24.1%) comorbidities. Use of medications with clinically demonstrated efficacy in PNDs was higher among patients with Pure PNDs (tricyclic antidepressants [Pure, 16.6%; Mixed, 10.1%]; 2nd generation antidepressants [Pure, 11.0%; Mixed, 9.7%]; and antiepileptics [Pure, 12.2%; Mixed, 2.6%]), whereas use of NSAIDs (Pure, 43.1%; Mixed, 65.2%) and opioids (Pure, 8.5%; Mixed, 14.3%) was higher among patients with Mixed PNDs. Average daily doses of select neuropathic pain-related medications among PND patients (Pure and Mixed) were lower than those recommended for neuropathic pain. Among both Pure and Mixed PND patients, use and doses of evidenced-based neuropathic pain-related medications was low, and lower than the use of NSAIDs (a medication class with no proven efficacy for PNDs) in each group, suggesting possible sub-optimal neuropathic pain management among these patients.
机译:缓解慢性疼痛是全球医疗保健的重点。了解疼痛性神经性疾病(PND)患者的医学概况和当前治疗模式对于开发有效的疼痛管理策略至关重要。因此,我们的目的是描述PND患者的人口统计学和临床​​特征及其止痛药的使用。使用全科医学研究数据库,我们以两种方式对PND进行分类:纯PND(包括糖尿病性神经病,带状疱疹后神经痛等; N = 16,690)和混合PND(包括伴有神经性受累的背部/颈部疼痛; N = 14,309) 。平均而言,PND患者为55岁(纯,55.4 [SD = 16.9]岁;混合,54.3 [SD = 16.4]岁)。三分之一以上的患者与其他慢性疼痛相关(纯37.5%;混合型37.1%),近四分之一与非疼痛相关(纯28.1%;混合型24.1%)。在纯PND患者中,使用具有临床证明的PND疗效的药物的比例更高(三环类抗抑郁药[纯,16.6%;混合,10.1%];第二代抗抑郁药[纯,11.0%;混合,9.7%];抗癫痫药[纯,分别为12.2%; 2.6%],而在PND混合型患者中,使用NSAIDs(纯43.1%;混合65.2%)和阿片类药物(纯8.5%;混合14.3%)的比例更高。 PND患者(纯和混合)中选择的与神经痛相关的药物的平均日剂量低于推荐用于神经痛的药物。在纯PND和混合PND患者中,每组中基于证据的神经性疼痛相关药物的使用和剂量均较低,且低于使用NSAIDs(PND的疗效尚未证实的药物类别),这表明可能是次优的这些患者的神经性疼痛管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号